Related Experiment Videos
Pharmacokinetics of 51W89: preliminary data
J M Hunter1, N B Eastwood, A H Boyd
1University Department of Anaesthesia, Royal Liverpool University Hospital, UK.
Acta Anaesthesiologica Scandinavica. Supplementum
|January 1, 1995
Summary
The study found that the elimination half-life of 1R cis-1
Area of Science:
- Pharmacology
- Nephrology
Background:
- Atracurium (51W89) is a neuromuscular blocking agent.
- Chronic renal failure impacts drug pharmacokinetics.
Purpose of the Study:
- To investigate the pharmacokinetics of 1R cis-1'R cis-isomer of atracurium (51W89) and its metabolite, laudanosine.
- To compare drug behavior in healthy individuals versus patients with chronic renal failure.
Main Methods:
- Administered a bolus dose of 51W89 (0.1 mg/kg) to 11 healthy patients and 12 patients with chronic renal failure.
- Monitored plasma concentrations for 480 minutes.
- Measured laudanosine metabolite levels.
Main Results:
- The elimination half-life of 51W89 was significantly longer in renal failure patients (38.9 min) compared to healthy controls (30.6 min).
- Plasma laudanosine levels were lower than those observed with atracurium besylate.
- Indicated a potentially prolonged effect of 51W89 in renal failure.
Conclusions:
- Renal failure significantly prolongs the elimination half-life of 1R cis-1'R cis-isomer of atracurium (51W89).
- Lower laudanosine levels suggest altered metabolism or distribution in renal failure.
- Clinical implications for dosing and monitoring 51W89 in patients with kidney disease warrant further investigation.